Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, May 14 2019

Full Issue

A Biotech Executive With Big Ideas Aims To Increase 'Healthspan' Not Necessarily Lifespan

Ned David talks about aging and finding ways to improve the process as we live longer than ever before. In other pharmaceutical news, New Jersey eases some restrictions around gifts and payments for drugmakers and more states join a broad coalition suing pharmaceutical companies over generic drug prices.

Stat: A Biotech Exec Seizes On Big Ideas, From Anti-Aging Therapies To Antibiotics

Nathaniel “Ned” David, the co-founder and president of Unity Biotechnology (UBX), is one of biotech’s big idea guys. Before starting Unity in 2011, David founded four other companies that raised $1.5 billion in financing and now employ 400 people. The idea behind Unity is particularly vast: The company is targeting the science around aging, and all the diseases that can result from it. Its first studies, due to read out over the next few years, are in arthritis and eye diseases like glaucoma and age-related macular degeneration. The goal, David says, is not to extend life, but to increase “healthspan,” the length of time during which people are healthy. (Herper, 5/14)

Stat: N.J. Finalizes Rules On Pharma Gifts To Doctors, Eases Meal Limits

After more than a year of debate, New Jersey eased some of the provisions in a controversial rule that governs the sort of gifts and payments that drug makers can give to doctors. In a filing last week, the state acceded to complaints from the restaurant and hospitality industry that the initial proposal on meals was too restrictive and unrealistic. However, New Jersey Attorney General Gurbir Grewal left in place a $10,000 annual cap on what physicians can earn from drug makers for such activities as promotional speaking and consulting. Research work, however, is exempt. (Silverman, 5/13)

Iowa Public Radio: Iowa AG Joins Lawsuit Alleging Drug Executives Conspired To Inflate Prices

Iowa Attorney General Tom Miller is one of 44 attorneys general who is taking part in a lawsuit alleging that 20 of the country's largest generic drug makers have conspired to inflate and manipulate drug prices. Miller said the suit argues that executives at drug manufactures Teva, Sandoz, Mylan, Pfizer and others had an "informal working relationship" to allocate markets and rig bids for more than 100 drugs. (Krebs, 5/13)

MPR: Minnesota Joins Multi-State Lawsuit Against Generic Drugmakers Over Prices

Minnesota Attorney General Keith Ellison said on Monday the state is joining dozens of others in suing generic drug manufacturers over prices. The lawsuit alleges that nearly two dozen drug companies reached tacit agreements to divide up the drug market and push prices higher to increase revenue. Generic drugs are copies of name-brand medications which are often prescribed as lower cost alternatives. (Nelson, 5/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF